Drug news

Shingrix approved in EU and Japan for the prevention of shingles (herpes zoster) and post-herpetic neuralgia. - GSK.

Read time: 1 mins

Last updated:24th Mar 2018

Published:24th Mar 2018

Source: Pharmawand

GlaxoSmithKline announced that the European Commission has approved Shingrix for the prevention of shingles (herpes zoster) and post-herpetic neuralgia (PHN) in adults aged 50 years or older. The GSK said the Japanese Ministry of Health, Labour and Welfare has also approved Shingrix for the prevention of shingles in adults aged 50 years or older.

It described Shingrix as a non-live, recombinant subunit adjuvanted vaccine given intramuscularly in two doses. In Japan the vaccine is registered to the Japan Vaccine Co., Ltd., a joint venture of GlaxoSmithKline and Daiichi Sankyo Co., Ltd.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Cidara Therapeutics reacquires global development and commercial rights to CD 388

Cidara Therapeutics, Inc. a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced that it has entered into a definitive agreement with Johnson & Johnsonto reacquire the exclusive global development and commercial rights to CD 388, which is in development for the prevention of all strains of influenza A and B

1 mins

Drug news

Cidara Therapeutics announces the divestiture of rezafungin rights to MundiPharma

Cidara Therapeutics, Inc. announced that it has entered into an asset purchase agreement with its current partner, Mundipharma, for the divestiture of rezafungin

1 min

Drug news

FINTEPLA (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Fintpla (fenfluramine) oral solution has been approved by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older

1 min

See all news